Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Pharmavizer AB
AB
Active
Org 5568335854
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2010 · 15 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Pharmavizer AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
1M
2021
0M
2022
0M
2023
0M
2024
0M
2025
EBITDA
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
0M
0%
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
608
131
65
−0
−30
Staff expenses
—
−64
−39
30
30
EBITDA
496
−7
−13
2
−9
Depreciation & amort.
−0
—
—
—
—
EBIT
496
−7
−13
2
−9
Net financials
—
0
1
1
0
Profit before tax
542
−7
54
3
−4
Tax
−116
−0
−13
−1
−1
Net profit
426
−7
41
2
−4
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
948
910
756
701
691
Equity
480
447
488
490
487
Long-term debt
0
—
—
—
—
Short-term debt
214
209
80
23
22
Total debt
214
209
80
23
22
Financial ratios
5-year trend
EBITDA margin
-913600.0%
This company
15.8%
Market median
-5782378% vs market
2021
2025
Equity ratio
70.4%
This company
38.2%
Market median
+84% vs market
2021
2025
Return on equity
-0.7%
This company
18.4%
Market median
-104% vs market
2021
2025
Net profit margin
-363400.0%
This company
8.1%
Market median
-4486520% vs market
2021
2025
Asset turnover
-0.04×
This company
1.12×
Market median
-104% vs market
2021
2025
Debt / equity
0.42×
This company
0.62×
Market median
+32% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Pharmavizer AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
